Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Core Viewpoint - Ensysce Biosciences, Inc. is advancing its pivotal Phase 3 clinical trial for PF614, a next-generation opioid designed to provide effective pain relief while incorporating built-in abuse and overdose protection [1] Enrollment Progress - The company has successfully enrolled 50% of the targeted subjects for an interim review in the Phase 3 clinical trial [1] - Enrollment commenced in late December 2025 and is progressing rapidly across three clinical sites in the U.S. [1] Clinical Sites - The clinical trial is being conducted at three locations: CenExel JBR in Salt Lake City, Utah; CenExel Atlanta in Decatur, Georgia; and ERG-HD Research, LLC in Houston, Texas [1]